Dr. Rahul Roy Chowdhury
DesignationSenior Consultant
SpecialtyGynecologic Oncologist
Experience 33 years of experience
HospitalManipal Hospital, Dhakuria
Languages SpokenBengali, English, Hindi
About Dr. Rahul Roy Chowdhury
- Dr. Rahul Roy Chowdhury is a highly experienced Gynaecologist and Gynaecological Oncologist with more than 33 years of clinical expertise.
- He specializes in the diagnosis and surgical treatment of gynaecological cancers including ovarian, cervical, endometrial, and vulvar cancers.
- His expertise includes advanced oncological procedures such as pelvic and upper abdominal surgeries, peritonectomies, and radical pelvic floor clearances.
- He is also skilled in minimally invasive laparoscopic procedures including laparoscopic pelvic and retroperitoneal nodal clearances and sentinel lymph node biopsies.
- Dr. Roy Chowdhury has extensive international experience and has contributed to clinical research and training in gynaecological oncology.
Specializations & Conditions Treated
Ovarian Cancer Treatment
Adrenal Cancer Treatment
Chemotherapy
Endometrial Cancer Treatment
Immunotherapy
Oral Cancer Treatment
Prostate Cancer Treatment
Radiation Therapy
Targeted Therapy
Vaginal Cancer Treatment
Education
MBBS
MRCOG
FRCOG
Work Experience of Dr. Rahul Roy Chowdhury
Consultant in Gynaecology and Gynaecological Oncology at Manipal Hospitals, Mukundapur, Kolkata.
Formerly practiced and trained in several prestigious hospitals in the United Kingdom.
Specialized training in Gynaecological Oncology at Oxford Cancer Centre, John Radcliffe Hospital, UK.
Experienced clinician scientist involved in clinical trials and research in advanced cervical and ovarian cancers.
Awards & Recognition
Local Mentor for In-Country IGCS Fellowship, India.
LMIC representative for the 1st Endometrial Cancer Consensus Conference for Clinical Research (ECCC-CR) held in Seoul, Korea in 2023.
Invited resource person for training consultants in Gynaecological Oncologic Surgery at Chittagong Medical College, Bangladesh.
Publications
In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer and its clinical implications.
Predominance of genomically defined A lineage of HPV16 over D lineage in Indian patients with cervical squamous cell carcinoma – Translational Oncology, 2021.
Incorporating patient-centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer – Gynecologic Oncology, 2021.
Intermittent PARP Inhibitor Regimen in Ovarian Cancer (IPIROC) exploratory study presented at IGCS Abstracts, 2023.
Our website uses cookies. By clicking on accept you give your consent to the use of cookies as per our Privacy Policy.